Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an immature viral particle that buds from the cell surface.

Although budding releases the virus from the host cell, the newly formed virion is not yet infectious. Full infectivity depends on viral maturation, which relies on the ordered cleavage of the Gag and Gag-Pol polyproteins. This step is catalyzed by the viral protease, an aspartyl protease encoded within the Gag-Pol polyprotein. Proteolytic processing generates individual structural proteins, including matrix, capsid, and nucleocapsid, and allows viral enzymes to adopt their active conformations. These cleavage events trigger a major reorganization of the virion’s internal structure, resulting in the condensed core typical of mature, infectious HIV particles.

Protease inhibitors are antiretroviral drugs that target this critical maturation step. By binding to the active site of the viral protease, these agents prevent cleavage of the viral polyproteins. As a result, virions released from infected cells remain structurally immature, with improperly processed proteins and a disordered internal architecture. While such particles can still bud from the host cell, they are noninfectious and cannot initiate productive infection. By blocking viral maturation, protease inhibitors reduce viral replication and limit HIV spread, making them an essential component of combination antiretroviral therapy.